Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC FIX Birch Dose Finding Study
NCT01639768Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Jul 2012
- Primary completion
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of Sublivac Birch in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Jul 2012; status: completed.
02
Drugs
Sublivac Birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01639768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639768.